Tetrahedron 70 (2014) 9565–9570

Contents lists available at ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

Tetrahedron Vol. 70, Issue 51, 2014

Contents

REPORT



ARTICLES





We have developed a safe, practical and reproducible process for the first fully synthetic Anti-HBV drug *N*-[*N*-benzoyl-*O*-(2-dimethylaminoethyl)-L-tyrosyl]-L-phenylalaninol (**Y101**) to allow preclinical and clinical development (see picture). Several kilograms of active pharmaceutical ingredient have been manufactured by this process to date. This material has been sufficient to provide for development as well as drug product manufacturing for early clinical studies.